TRexBio Announces Closing of Initial Public Offering

Impact · against what's priced in

TRex Bio successfully raised approximately $116.67 million through its IPO to fund clinical-stage operations. This provides the company with the necessary capital runway to advance its immunoregulatory medicine pipeline.

TRXB+0.60: No priced-in read yet
In context: The company closed its IPO of 8,333,334 shares at $14.00 per share, securing $116.67 million in gross proceeds to fund its clinical-stage operations.
Read from the article alone

TRexBio Announces Closing of Initial Public Offering

ipo
healthcare
biotech
TRXB
common stock
public offering

Search tags

TRexBio Announces Closing of Initial Public Offering

What matters in this story

How each ticker is affected

BMY Reports Mixed Phase III Trial Results, Stock Down

TRexBio Announces Closing of Initial Public Offering

What matters in this story

How each ticker is affected

BMY Reports Mixed Phase III Trial Results, Stock Down

Track these names every morning.

TGTX Stock Rises 60% in 6 Months: Here's What You Should Know

Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases

Why It May Be A November To Remember

Merck (MRK) Dips More Than Broader Market: What You Should Know

TRexBio Announces Closing of Initial Public Offering

What matters in this story

How each ticker is affected

Next reads from the same story arc

BMY Reports Mixed Phase III Trial Results, Stock Down

TRexBio Announces Closing of Initial Public Offering

What matters in this story

How each ticker is affected

Next reads from the same story arc

BMY Reports Mixed Phase III Trial Results, Stock Down

Track these names every morning.

TGTX Stock Rises 60% in 6 Months: Here's What You Should Know

Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases

Why It May Be A November To Remember

Merck (MRK) Dips More Than Broader Market: What You Should Know